Systematic Review
AGTR1rs5186 Polymorphism Is Associated with the Risk of Restenosis after Percutaneous Coronary Intervention: A Meta-Analysis

Feng Lv 1,2, Yufeng Jiang 1, Yebao Wang 1, Ting Zhang 1 and Yafeng Zhou 1,*

1 Department of Cardiology, Suzhou Dushu Lake Hospital, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou 215125, China
2 Department of Cardiology, Shengzhou People’s Hospital, The First Affiliated Hospital of Zhejiang University Shengzhou Branch, Shengzhou 312400, China
* Correspondence: zhouyafeng73@126.com

Abstract: Background: Progress has been made in genetic investigations on restenosis for the past 20 years, many studies regarding AGTR1 rs5186 polymorphism and restenosis after percutaneous coronary intervention (PCI) have been published, but the result remains controversial. The study aimed to explore the relationship between rs5186 polymorphism and the risk of restenosis after PCI.

Methods: We performed a systematic search on PubMed, Web of Science, Embase, CNKI, and Wan Fang databases up to December 2021. Two authors individually extracted all useful data of each study involved in this meta-analysis and assessed the study quality using the Newcastle-Ottawa scale. Odds ratios (ORs) and 95% confidence intervals (CIs) were combined in different genetic models for evaluation using a random-effects model or fixed-effect model. Results: There were eventually 8 studies of 1111 cases and 4097 controls eligible for this meta-analysis. Significant associations were found between rs5186 polymorphism and restenosis after PCI. Allelic (OR: 1.31, 95% CI: 1.17–1.47, \(p < 0.001\)), homozygous (OR: 1.90, 95% CI: 1.50–2.44, \(p < 0.001\)), heterozygous (OR: 1.10, 95% CI: 0.93–1.29, \(p = 0.27\)), recessive (OR: 1.80, 95% CI: 1.37–2.36, \(p < 0.001\)), dominant genetic model (OR: 1.24, 95% CI: 1.06–1.44, \(p = 0.006\)). Subgroup analyses indicated a significant association in Asians.

Conclusions: The rs5186 polymorphism in the AGTR1 gene increases the risk of restenosis after PCI in Asians significantly.

Keywords: cardiovascular disease; rs5186; percutaneous coronary intervention; polymorphism

1. Introduction

Cardiovascular disease (CVD) remains a major cause of premature mortality and rising healthcare costs [1]. The CVD burden continues its decades-long rise in almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries [2]. There is an urgent need to implement interventions.

Coronary atherosclerotic heart disease (CHD) is one of the major cardiovascular diseases. In addition to medical therapy, percutaneous coronary intervention (PCI) has become an important treatment for CHD. Primary PCI modalities include percutaneous transluminal coronary balloon angioplasty, coronary stenting, and others, which reduce CHD-related mortality significantly [3]. However, the disadvantages of coronary restenosis after PCI have become increasingly obvious. Although the rate of restenosis has decreased in recent years with second-generation drug-eluting stents, restenosis after PCI still affects patient outcomes [4–6]. It has been well-reported that age [7], hypertension [8], diabetes [9], and dyslipidemia [10] are risk factors for restenosis. However, coronary lesion-specific interventional procedures can also contribute to restenosis [11].
The pathophysiological of restenosis after PCI is damage to vascular endothelial cells, leading to hyperplasia of the neovascular endothelium. Angiotensin II in the renal angiotensin aldosterone system (RAAS) would stimulate the expression of smooth muscle cell growth factor to promote smooth muscle cell hyperplasia, migration, and thus the occurrence of restenosis [12]. With the rapid development of sequencing technology, much progress has been made in genetic investigations on restenosis. For the past 20 years, many case-control-designed studies [13–20] regarding the Ang II type 1 receptor (AGTR1) rs5186 polymorphism and restenosis after PCI have been published. Due to the small sample size and low statistical power of individual studies, the consolidated result is still controversial. In this paper, we conducted a meta-analysis of the rs5186 gene polymorphism in all patients with restenosis versus no after PCI from the enrolled studies to investigate the association between rs5186 polymorphism and the risk of restenosis after PCI.

2. Materials and Methods

We followed the methods of Jiang et al. [21] to perform our meta-analysis. Since this meta-analysis was based on published studies, patient consent and ethical approval were not required.

2.1. Search Strategy

A systematic search was conducted in the PubMed, Web of Science, Embase, CNKI, and Wan Fang databases from inception to December 2021 with no language restrictions, combined with a manual search of reference lists from the identified articles. The following terms were used in the literature search: restenosis, rs5186, AGTR1, A1166, polymorphism, variant, and mutation. This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [22]. The protocol for this systematic review was registered on INPLASY (International Platform of Registered Systematic Review and Meta-analysis Protocols) (Unique ID number) and is available in full on inplasy.com (ID: INPLASY2022110054).

2.2. Selection and Exclusion Criteria

Studies meeting the following criteria were included: (1) Case-control studies; (2) Investigating the association of the rs5186 polymorphism and risk of restenosis; (3) Studies had data of odds ratios (ORs) and 95% confidence intervals (95% CI) or had sufficient data to calculate it.

2.3. Data Extraction

Two of the authors independently extracted data from eligible studies. The process was as follows: (1) read the article title and exclude duplicate studies; (2) Titles and abstracts were read, and irrelevant literature was excluded; (3) The full texts were read in detail, and the literature that met the inclusion and exclusion criteria were finally identified. Conflicts were discussed with a third reviewer. Extraction of study data: author, publication year, country, ethnicity, number of patients, source of controls, PCI type, genotyping method, and genotype distribution. The 9-point Newcastle-Ottawa Scale (NOS) was used to assess the methodological quality included [23].

2.4. Statistical Analysis

This meta-analysis was performed using Stata version 14.0. We did Hardy-Weinberg equilibrium (HWE) tests for every study included. We explored the associations between rs5186 polymorphism and risk of restenosis by combining ORs and 95% CIs under a random-effect or fixed model. A random-effects model for pooled analysis would be adopted when $I^2 >50\%$ indicating heterogeneity. Otherwise, the fixed-effect model would be used. We also performed subgroup analyses to identify the underlying heterogeneity according to ethnicity, study sample size, and PCI type. The analyses were conducted in 5 genetic models: allele (A allele distribution frequency of rs5186 polymorphism),
homozygote model (AA vs. CC), heterozygote model (AC vs. AA), recessive model (CC vs. AC + AA) and dominant model (CC + CC vs. AA). A sensitivity analysis was performed to evaluate the stability of the results. We investigated publication bias by calculating the Egger test and drawing the Begg funnel plot.

3. Results

3.1. Study Characteristics

The search of the five databases identified 51 records. After removing the duplicated studies, there were 34 studies left for screening. Twenty-one irrelevant pieces of literature were excluded after reading the title and abstract of the article. Finally, 13 studies were read in full-text, and five full-text articles were excluded because of unmatched study design (n = 2), insufficient data (n = 2), and not relevant to restenosis (n = 1). Figure 1 shows the complete procedure of study selection and exclusion. There were eventually 8 studies [13–20] of 1111 cases and 4097 controls eligible for this meta-analysis. Characteristics of the studies included in the meta-analysis are shown in Table 1. All articles were published in English. The sample sizes ranged from 111 to 2946 of all eligible studies. The race of the included studies were Asian (China, n = 3) and Caucasian (France, Germany, Russia, The Netherlands, n = 5). All included studies fitted in with the HWE test. The results of NOS are shown in Table 2. The NOS of all eligible studies in our meta-analysis was >6 points, representing a good study quality. Genotype distribution and allele frequency in cases and controls of each study are shown in Table 3.

Figure 1. The PRISMA flow diagram of the study selection and exclusion.
Table 1. Characteristics of the studies included for meta-analysis.

| Author          | Year | Country     | Ethnicity | Age (Years) | Gender (M/F) | Comorbidities | Source of Controls | Genotyping Method | Polymorphism | NOS Score | HWE Test |
|-----------------|------|-------------|-----------|-------------|--------------|---------------|--------------------|-------------------|--------------|-----------|----------|
| Hamon et al. [13] | 1998 | France      | Caucasian | NR          | 229/42       | HTN, diabetes, CAD | HB                 | PCR              | rs5186      | 7         | 0.35     |
| Volzke et al. [14] | 2000 | Germany     | Caucasian | 59.9 (8.9)  | 60.6 (8.6)   | HTN, diabetes, CAD | HB                 | PCR–RFLP         | rs5186      | 8         | 0.96     |
| Hertwig et al. [15] | 2002 | Germany     | Caucasian | 59.7 (7.9)  | 58.7 (9.2)   | HTN, diabetes, CAD | HB                 | PCR–RFLP         | rs5186      | 7         | 0.60     |
| Wijpkema et al. [16] | 2006 | The Netherlands | Caucasian | 62 (11)     | 2121/825     | HTN, diabetes, CAD | HB                 | PCR–RFLP         | rs5186      | 8         | 0.12     |
| Li et al. [17]   | 2015 | China       | Asian     | 72.2 (4.2)  | 72.2 (4.1)   | HTN, diabetes, CAD | HB                 | PCR–RFLP         | rs5186      | 6         | 0.04     |
| Zhu et al. [18]  | 2017 | China       | Asian     | 65.3 (11.5) | 63.7 (11.6)  | HTN, diabetes, CAD | HB                 | PCR              | rs5186      | 7         | 0.36     |
| Zeng et al. [19] | 2017 | China       | Asian     | 61.3 (6)    | 60.5 (6.15)  | HTN, diabetes, CAD | HB                 | PCR              | rs5186      | 8         | 0.65     |
| Azova et al. [20] | 2021 | Russian     | Caucasian | 60 (10.1)   | 58.8 (8)     | HTN, diabetes, CAD | HB                 | PCR–RFLP         | rs5186      | 7         | 0.20     |

Case-control design was used in all included studies. PCR–RFLP = polymerase chain reaction restriction fragment length polymorphism; year = publication year; NOS = Newcastle-Ottawa scale; HWE = Hardy–Weinberg equilibrium; HB = hospital-based; HTN = hypertension; CAD = coronary artery disease. Case-control design was used in all included studies. PCR–RFLP = polymerase chain reaction restriction fragment length polymorphism; year = publication year; NOS = Newcastle-Ottawa scale; HWE = Hardy–Weinberg equilibrium; HB = hospital-based; HTN = hypertension; CAD = coronary artery disease.
Table 2. The results of Newcastle-Ottawa Scale.

| Author                | Selection | Comparability | Exposure |
|-----------------------|-----------|---------------|----------|
| Hamon et al. [13]     | ***       | **            |          |
| Volzke et al. [14]    | ***       | **            | ***      |
| Hertwig et al. [15]   | ***       | **            |          |
| Wijpkema et al. [16]  | ***       | **            | ***      |
| Li et al. [17]        | **        | **            | **       |
| Zhu et al. [18]       | ***       | **            |          |
| Zeng et al. [19]      | ***       | **            | ***      |
| Azova et al. [20]     | ***       | **            |          |

The quality of each study was assessed based on a 9-point Newcastle-Ottawa scale. The maximum points for selection, comparability and exposure in the table, (4 points for selection, 2 points for comparability, and 3 points for exposure). Each * is 1 point in the table. All eligible studies in our meta-analysis were >6 points.

Table 3. ANT1R rs5186 polymorphism genotype distribution and allele frequency in cases and controls.

| Genotype (N) | Allele Frequency (N, %) |
|--------------|-------------------------|
|              | Cases                   | Controls |
|              | Total AA AC CC Total AA AC CC C A RAF C A RAF |
| Hamon et al. [13] | 103 55 36 12 168 84 66 18 146 0.71 102 234 0.70 |
| Volzke et al. [14] | 160 80 64 16 351 195 133 23 224 0.70 179 523 0.75 |
| Hertwig et al. [15] | 46 23 19 4 99 52 38 9 65 0.71 56 142 0.72 |
| Wijpkema et al. [16] | 324 150 130 44 2622 1271 1133 218 430 0.66 1569 3675 0.70 |
| Li et al. [17] | 307 116 100 91 176 100 55 21 332 0.54 97 255 0.72 |
| Zhu et al. [18] | 65 56 9 0 251 222 26 3 9 121 0.93 32 470 0.94 |
| Zeng et al. [19] | 54 45 9 0 371 310 59 2 9 99 0.92 63 679 0.92 |
| Azova et al. [20] | 52 25 17 10 59 34 19 6 37 0.64 31 87 0.74 |

A case-control design was used in all included studies. RAF = risk allele frequency; risk allele = C allele.

3.2. Quantitative Synthesis

The meta-analysis indicated a significant association between AGTR1 rs5186 polymorphism and restenosis after PCI. Allelic (OR: 1.31, 95% CI: 1.17–1.47, \( p < 0.001 \)), homozygous (OR: 1.90, 95% CI: 1.50–2.44, \( p < 0.001 \)), heterozygous (OR: 1.10, 95% CI: 0.93–1.29, \( p = 0.27 \)), recessive (OR: 1.80, 95% CI: 1.37–2.36, \( p < 0.001 \)), dominant genetic model (OR: 1.24, 95% CI: 1.06–1.44, \( p = 0.006 \)) in the whole population (Figure 2).

Figure 2. Cont.
Figure 2. Forest plot from the meta-analysis on the association of the rs5186 polymorphism and risk of restenosis after PCI. (A) allele model: C vs. A; (B) homozygote model: CC vs. AA; (C) heterozygote model: AC vs. AA; (D) recessive model: CC vs. AC + AA; and (E) dominant model: CC + AC vs. AA. CI = confidence interval, OR = odds ratio [13–20].

In the subgroup analyses by ethnicity (Figure 3), the association grew stronger with higher ORs in Asian under all genetic models: allelic (OR: 1.89, 95% CI: 1.48–2.40, \( p < 0.001 \)), homozygous (OR: 3.35, 95% CI: 1.99–5.64, \( p < 0.001 \)), heterozygous (OR: 1.42, 95% CI: 1.02–1.98, \( p = 0.04 \)), recessive (OR: 2.89, 95% CI: 1.75–4.78, \( p < 0.001 \)), dominant genetic model (OR: 1.76, 95% CI: 1.30–2.38, \( p < 0.001 \)). In the Caucasian subgroup, we also found association under allelic (OR: 1.18, 95% CI: 1.03–1.34, \( p = 0.02 \)), homozygous (OR: 1.58, 95% CI: 1.19–2.09, \( p = 0.002 \)) recessive (OR: 1.59, 95% CI: 1.21–2.09, \( p = 0.01 \)). In summary, our meta-analysis suggested that rs5186 polymorphism in the AGTR1 gene increased the risk of restenosis after PCI, particularly in Asians. We also carried out subgroup analyses according to sample size, and PCI type. The detailed information is presented in Table 4. A similar association was observed in both sample size (≥400) and PCI type (stent) subgroups that rs5186 polymorphisms in the AGTR1 gene increased the risk of restenosis after PCI.

3.3. Sensitivity Analysis

We carried out the sensitivity analysis to find whether the omission of each study would change the pooled ORs quantitatively. No changed results are shown after the individual study was omitted in Figure 4, which supplied evidence to prove the increased risk of the rs5186 polymorphism to restenosis after PCI (Figure 4).
Table 4. Subgroup analyses of the association between AGTR1 rs5186 polymorphism and restenosis.

| Subgroup       | Number | Odds Ratio | 95% Confident Interval | p Value | I² (%) |
|----------------|--------|------------|------------------------|---------|--------|
| **Allele model** |        |            |                        |         |        |
| **Ethnicity**  | Caucasian | 5     | 1.18                  | (1.03, 1.34) | 0.02   | 0.0   |
|               | Asian    | 3     | 1.89                  | (1.48, 2.40) | <0.001 | 69    |
| **Sample Size** | ≥400       | 4     | 1.37                  | (1.21, 1.56) | <0.001 | 80    |
|               | <400     | 4     | 1.09                  | (0.84, 1.41) | 0.52   | 0.0   |
| **PCI type**   | PTCA     | 3     | 1.11                  | (0.90, 1.38) | 0.324  | 0.0   |
|               | Stent    | 5     | 1.40                  | (1.22, 1.60) | <0.001 | 74    |
| **Homozygote model** |        |        |                        |         |        |
| **Ethnicity**  | Caucasian | 5     | 1.58                  | (1.19, 2.09) | 0.002  | 0.0   |
|               | Asian    | 3     | 3.35                  | (1.99, 5.64) | <0.001 | 0.0   |
| **Sample Size** | ≥400       | 4     | 2.15                  | (1.64, 2.82) | <0.001 | 50    |
|               | <400     | 4     | 1.19                  | (0.68, 2.10) | 0.55   | 0.0   |
| **PCI type**   | PTCA     | 3     | 1.30                  | (0.80, 2.11) | 0.29   | 0.0   |
|               | Stent    | 5     | 2.21                  | (1.66, 2.93) | <0.001 | 37    |
| **Heterozygote model** |        |        |                        |         |        |
| **Ethnicity**  | Caucasian | 5     | 1.01                  | (0.84, 1.22) | 0.88   | 0.0   |
|               | Asian    | 3     | 1.42                  | (1.02, 1.98) | 0.04   | 0.0   |
| **Sample Size** | ≥400       | 4     | 1.11                  | (0.93, 1.33) | 0.26   | 20    |
|               | <400     | 4     | 1.04                  | (0.73, 1.47) | 0.84   | 0.0   |
| **PCI type**   | PTCA     | 3     | 1.05                  | (0.79, 1.41) | 0.74   | 0.0   |
|               | Stent    | 5     | 1.12                  | (0.92, 1.35) | 0.27   | 0.0   |
| **Recessive model** |        |        |                        |         |        |
| **Ethnicity**  | Caucasian | 5     | 1.59                  | (1.21, 2.08) | 0.01   | 0.0   |
|               | Asian    | 3     | 2.89                  | (1.75, 4.78) | <0.001 | 0.0   |
| **Sample Size** | ≥400       | 4     | 2.02                  | (1.44, 2.84) | <0.001 | 25    |
|               | <400     | 4     | 1.23                  | (0.71, 2.14) | 0.46   | 0.0   |
| **PCI type**   | PTCA     | 3     | 1.29                  | (0.81, 2.06) | 0.29   | 0.0   |
|               | Stent    | 5     | 2.07                  | (1.53, 2.81) | <0.001 | 5.5   |
| **Dominant model** |        |        |                        |         |        |
| **Ethnicity**  | Caucasian | 5     | 1.11                  | (0.94, 1.32) | 0.23   | 0.0   |
|               | Asian    | 3     | 1.76                  | (1.30, 2.38) | <0.001 | 49    |
| **Sample Size** | ≥400       | 4     | 1.27                  | (1.09, 1.52) | <0.001 | 69    |
|               | <400     | 4     | 1.07                  | (0.77, 1.48) | 0.69   | 0.0   |
| **PCI type**   | PTCA     | 3     | 1.10                  | (0.83, 1.44) | 0.51   | 0.0   |
|               | Stent    | 5     | 1.24                  | (1.06, 1.44) | 0.004  | 59    |

Figure 3. Cont.
Figure 3. Subgroup meta-analysis by ethnicity of the association of the rs5186 polymorphism and risk of restenosis after PCI. (A) allele model: C vs. A; (B) homozygote model: CC vs. AA; (C) heterozygote model: AC vs. AA; (D) recessive model: CC vs. AC + AA; and (E) dominant model: CC + AC vs. AA. CI = confidence interval, OR = odds ratio [13–20].

3.3. Sensitivity Analysis

We carried out the sensitivity analysis to find whether the omission of each study would change the pooled ORs quantitatively. No changed results are shown after the individual study was omitted in Figure 4, which supplied evidence to prove the increased risk of the rs5186 polymorphism to restenosis after PCI (Figure 4).

Figure 4. Sensitivity analysis of the pooled OR coefficients on the relationship between rs5186 polymorphism and risk of restenosis after PCI. CI = confidence interval, OR = odds ratio [13–20].

3.4. Publication Bias

We computed the Egger test and drew the Begg funnel plot to estimate the publication bias. We could see that all eight studies were distributed on two sides of the Begg funnel plot (Figure 5), which implied no publication bias in our meta-analysis (Egger test: p = 0.59).
was no publication bias in our meta-analysis.

we also conducted subgroup analyses according to sample size and PCI type. A similar and the relationship with restenosis after PCI. All results indicated that the rs5186 polymorphism was a risk factor for restenosis after PCI [18].

polymorphism would increase the risk of restenosis after PCI. Subgroup analyses showed hyperplasia and are associated with restenosis following intracoronary stent placement [16,25]. With the rapid development of sequencing technology, much progress has been made in the genetic investigation of restenosis. Many studies [13–20] found that the rs5186 polymorphism of AGTR1 was a risk factor for restenosis after PCI [18].

Our meta-analysis consolidated eight eligible studies on the rs5186 polymorphism of AGTR1 and the relationship with restenosis after PCI. All results indicated that the rs5186 polymorphism would increase the risk of restenosis after PCI. Subgroup analyses showed a higher risk of restenosis after PCI in subjects with the risk allele in the Asian population; we also conducted subgroup analyses according to sample size and PCI type. A similar association was observed in both sample size (≥400) and PCI type (stent) subgroups that rs5186 polymorphism in the AGTR1 gene increase the risk of restenosis after PCI. There was no publication bias in our meta-analysis.

Limitations of our meta-analysis should be acknowledged. First, all eight studies included in this meta-analysis were written in English and Chinese, so studies in other languages and possibly unpublished articles did not attend, which may cause selection bias. Second, there were no studies including Africans. The sample size of three studies, including Asians, was less than five studies, including Caucasians in this meta-analysis, which may influence the results. Third, genetic susceptibility may also depend on the coincidence of several gene polymorphisms acting together, which may influence the results.

4. Discussion

CVD is the leading cause of global mortality. Prevalent cases of total CVD nearly doubled from 271 million in 1990 to 523 million in 2019, and the number of CVD deaths steadily increased from 12.1 million in 1990, reaching 18.6 million in 2019 [2]. CHD, as one of the major CVD, has received more attention than before. Despite great progress in reducing CHD deaths over the past decades. Percutaneous coronary intervention (PCI) is an alternative to revascularization in patients with CAD. Although intracoronary stent implantation has been shown to reduce coronary vessel restenosis significantly, restenosis problems remain even after drug-eluting stents become one of the most promising techniques in the current field of interventional cardiology. Mechanisms leading to restenosis after balloon angioplasty include elastic recoil and vascular remodeling. Excessive neointima formation, a process resulting from smooth muscle cell proliferation and extracellular matrix synthesis, is also a major cause of luminal restenosis after PCI.

The renal angiotensin aldosterone system (RAAS) has been implicated in the development and progression of neointimal hyperplasia predominantly through angiotensin II(Ang II) [24] Angiotensin-converting enzyme converts angiotensin I (Ang I) to Ang II which promotes the migration and proliferation of VSMCs, causes vasoconstriction and regulates expression of adhesion molecules via its major cellular receptor, AGTR1. Genes regulating levels and activity of the RAAS contribute to vasoconstriction and neointimal hyperplasia and are associated with restenosis following intracoronary stent placement [16,25].

Figure 5. Begg’s funnel plot with pseudo 95% confidence limits.
We finally concluded that the rs5186 polymorphism in the AGTR1 gene increases the risk of restenosis after PCI in Asians. It could be a promising locus for genetic therapy in the clinical management of restenosis after PCI. More case-control studies need to be carried out to further validate and strengthen the conclusion of this meta-analysis.

Author Contributions: Data curation, F.L. and Y.W.; writing—original draft preparation, F.L.; writing—review and editing, F.L., Y.J. and T.Z.; supervision, Y.J. and Y.Z.; funding acquisition, Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by grants from the National Natural Science Foundation of China (81873486), the Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology (BE2022754), Clinical Medicine Expert Team (Class A) of Jinji Lake Health Talents Program of Suzhou Industrial Park (SZYQTD202102), Suzhou Key Discipline for Medicine (SZXK202129), Demonstration of Scientific and Technological Innovation Project (SKY2021002), Suzhou Dedicated Project on Diagnosis and Treatment Technology of Major Diseases (LCZX202132), Research on Collaborative Innovation of medical engineering combination (SZM2021014). The funders had no roles in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement: Since this meta-analysis was in view of published studies, ethical approval was not required.

Informed Consent Statement: Since this meta-analysis was in view of published studies, patient consent was not required.

Data Availability Statement: The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Vos, T.; Lim, S.S.; Abbafati, C.; Abbas, K.M.; Abbasi, M.; Abbasisfard, M.; Abbasi-Kangevari, M.; Abastabar, H.; Abd-Allah, F.; Abdelalim, A.; et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. [CrossRef]
2. Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global Burden of Cardiovascular Disease and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [CrossRef] [PubMed]
3. Borovac, J.A.; D’Amario, D.; Vergallo, R.; Porto, I.; Bisignani, A.; Galli, M.; Annibali, G.; Montone, R.A.; Leone, A.M.; Niccoli, G.; et al. Neoatherosclerosis after drug-eluting stent implatation: A novel clinical and therapeutic challenge. Eur. Hear. J.-Cardiov. Pharmacother. 2019, 5, 105–116. [CrossRef] [PubMed]
4. Galløe, A.M.; Kelbæk, H.; Thuesen, L.; Hansen, H.S.; Ravkilde, J.; Hansen, P.R.; Christiansen, E.H.; Abildgaard, U.; Stephansen, G.; Lassen, J.F.; et al. 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. J. Am. Coll. Cardiol. 2017, 69, 616–624. [CrossRef]
5. Benaa, K.H.; Mannsverk, J.; Wiseth, R.; Aaberge, L.; Myreng, Y.; Nygård, O.; Nilsen, D.W.; Klaw, N.-E.; Uchto, M.; Trovik, T.; et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N. Engl. J. Med. 2016, 375, 1242–1252. [CrossRef]
6. Sabaté, M.; Brugaletta, S.; Cequier, A.; Iglesias, A.; Serra, A.; Jiménez-Quevedo, P.; Mainar, V.; Campo, G.; Tespili, M.; den Heijer, P.; et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet 2016, 387, 357–366. [CrossRef]
7. Miki, K.; Fujii, K.; Kawasaki, D.; Shibuya, M.; Fukunaga, M.; Imanaka, T.; Tamaru, H.; Sumiyoshi, A.; Nishimura, M.; Horimatsu, T.; et al. Intravascular Ultrasound–Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery. J. Endovasc. Ther. 2016, 23, 424–432. [CrossRef]
8. Prasad, A.M.; Morgan, D.A.; Nuno, D.W.; Ketsawatsomkron, P.; Bair, T.B.; Venema, A.N.; Dibbern, M.E.; Kutschke, W.J.; Weiss, R.M.; Lamping, K.G.; et al. Calcium/Calmodulin-Dependent Kinase II Inhibition in Smooth Muscle Reduces Angiotensin II–Induced Hypertension by Controlling Aortic Remodeling and Baroreceptor Function. J. Am. Heart Assoc. 2015, 4, e001949. [CrossRef]
9. Wang, W.; Weihrauch, D.; Kersten, J.R.; Toth, J.M.; Passerini, A.G.; Rajamani, A.; Schrepfer, S.; LaDisa, J.F. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am. J. Physiol. Circ. Physiol. 2015, 309, H1130–H1140. [CrossRef]
10. Qin, Z.; Zheng, F-W.; Zeng, C.; Zhou, K.; Geng, Y.; Wang, J-L.; Li, Y-P.; Ji, Q-W.; Zhou, Y-J. Elevated Levels of Very Low-density Lipoprotein Cholesterol Independently Associated with In-stent Restenosis in Diabetic Patients after Drug-eluting Stent Implantation. Chin. Med. J. Engl. 2017, 130, 2326–2332. [CrossRef]
11. Alraies, M.C.; Darmoch, F.; Tummala, R.; Waksman, R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. *World J. Cardiol.* 2017, 9, 640–651. [CrossRef] [PubMed]

12. Langeveld, B.; Roks, A.J.M.; Tio, R.A.; Voors, A.A.; Zijlstra, F.; van Gilst, W.H. Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. *J. Cardiovasc. Pharmacol.* 2005, 45, 88–98. [CrossRef] [PubMed]

13. Hamon, M.; Amant, C.; Bauters, C.; Richard, F.; Helbecque, N.; Passard, F.; McFadden, E.P.; Lablanche, J.-M.; Bertrand, M.E.; Amouyal, P. Dual Determination of Angiotensin-Converting Enzyme and Angiotensin-II Type 1 Receptor Genotypes as Predictors of Restenosis After Coronary Angioplasty. *Am. J. Cardiol.* 1998, 81, 79–81. [CrossRef]

14. Völzke, H.; Hertwig, S.; Rettig, R.; Motz, W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. *Clin. Sci.* 2000, 99, 19–25. [CrossRef]

15. Hertwig, S.; Völzke, H.; Robinson, D.M.; Motz, W.; Rettig, R. Angiotensinogen M235T gene polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angiography. *Clin. Sci.* 2002, 103, 101–106. [CrossRef]

16. Wijpkema, J.S.; van Haelst, P.L.; Monraats, P.S.; Bruinenberg, M.; Zwinderman, A.H.; Zijlstra, F.; van der Steege, G.; de Winter, R.J.; Doevendans, P.A.F.M.; Waltenberger, J.; et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. *Pharmacogenet. Genomics* 2006, 16, 331–337. [CrossRef]

17. Li, Y.; Chen, F.; Zhang, X.; Gao, Y.; Wu, C.; Li, H.; Zhang, Y. Angiotensin type 1 receptor A1166C gene polymorphism is associated with endothelial dysfunction and in-stent restenosis after percutaneous coronary intervention. *Int. J. Clin. Exp. Pathol.* 2015, 8, 7350–7357.

18. Zhu, M.; Yang, M.; Lin, J.; Zhu, H.; Lu, Y.; Wang, B.; Xue, Y.; Fang, C.; Tang, L.; Xu, B.; et al. Association of seven renin angiotensin system gene polymorphisms with restenosis in patients following coronary stenting. *J. Renin-Angiotensin-Aldosterone Syst.* 2017, 18, 147032031668877. [CrossRef]

19. Zeng, W.; Zhang, R.; Li, R.; Luo, J.; Hu, X. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent. *PloS ONE* 2017, 12, e0170964. [CrossRef]

20. Azova, M.; Timizheva, K.; Aissa, A.A.; Blagonravov, M.; Gigani, O.; Aghajanyan, A.; Tskhovrebova, L. Gene Polymorphisms of the Renin-Angiotensin-Aldosterone System as Risk Factors for the Development of In-Stent Restenosis in Patients with Stable Coro

21. Balakumar, P.; Jagadeesh, G. A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. *Cell Signal* 2014, 26, 2147–2160. [CrossRef]